MDV Medivation

SAN FRANCISCO, Nov. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that it will hold a conference call to provide an update on the clinical development plan and milestones for its lead product candidate Dimebon(TM). David Hung, M.D., president and chief executive officer, will host the call beginning at 1:00 p.m. Eastern time (10:00 a.m. Pacific time) on Wednesday, November 15. Dimebon, an orally available small molecule, has been shown to inhibit neuron (nerve cell) death in preclinical models of Alzheimer's disease and Huntington's disease, making it a novel potential treatment for many neurodegenerative diseases. In a six-month, randomized, double-blinded, placebo-controlled Phase 2 clinical trial of 183 patients with mild to moderate Alzheimer's disease, announced in September 2006, Dimebon was well tolerated and met all five efficacy endpoints with strong statistical significance compared to placebo. An extension study of the Phase 2 trial, which allows patients to continue treatment for up to 12 months in the same treatment group to which they originally were randomized, is currently ongoing. Medivation is also evaluating Dimebon in an ongoing Phase 1-2a trial in patients with Huntington's disease in collaboration with the Huntington Study Group. Teleconference/Webcast Details To participate in the live call by telephone, please dial 800-497-0451 from the U.S. or 706-758-3306 internationally. The conference ID is 1678449. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com/. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A telephone replay will be available beginning approximately two hours after the completion of the call through November 22 by dialing 800-642-1687 from the U.S. or 706-645-9291 internationally. The replay passcode is 1678449. A replay of the webcast will be available on the company's website for 30 days. About Medivation Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com/. This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward- looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates have been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005, and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2006, and June 30, 2006, include more information about factors that could affect the Company's financial and operating results. DATASOURCE: Medivation, Inc. CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for Medivation Web site: http://www.medivation.com/

Copyright